최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기생명과학회지 = Journal of life science, v.29 no.6 = no.230, 2019년, pp.679 - 687
진수정 (동의대학교 블루바이오소재개발센터) , 오유나 (동의대학교 블루바이오소재개발센터) , 정현영 (동의대학교 블루바이오소재개발센터) , 윤희정 (동의대학교 공과대학 바이오응용공학부) , 박정하 (동의대학교 공과대학 바이오응용공학부) , 권현주 (동의대학교 블루바이오소재개발센터) , 김병우 (동의대학교 블루바이오소재개발센터)
Litsea populifolia, a plant species of the Lauraceae family, is widely distributed in the tropical and subtropical areas of Asia. The phylogenetic relationships and botanical characteristics of L. populifolia have been reported; however, its anti-oxidative and anti-cancer activities remain unclear. ...
핵심어 | 질문 | 논문에서 추출한 답변 |
---|---|---|
세포주기는 무엇에 의해 다음 단계로 진행되는가? | 세포주기는 cyclin-dependent kinase (CDK)와 cyclin 복합체(CDK/cyclin complex)의 활성화에 의해 다음 단계로 진행되며, CDK/cyclin complex의 활성제어에 의해 세포주기가 조절된다. 현재까지 보고된 바로는 CDK 저해제로 알려진 p21, p27 등에 의해 CDK 활성이 저해되어 cell cycle arrest가 야기되며, 종양억제인자인 p53에 의해 p21의 발현이 증가되는 것으로 알려져 있다[2, 35, 38]. | |
Litsea populifolia는 무엇인가? | Litsea populifolia는 녹나무과(Laurel) 녹나무속(Lauraceae)에 속하는 관목으로 아시아의 열대 및 아열대 지역에 위치하고 있으며, 일부 종은 북한 또는 남아메리카에서도 발견된다. 현재까지 L. | |
현재까지 진행되어 온 Litsea populifolia 관련 연구 분야는 무엇인가? | 현재까지 L. populifolia의 생육특성 및 계통학적 연구가 진행되어 왔으나, 생리활성에 관해서는 전혀 밝혀진 바가 없다[34]. 따라서, 본 연구에서는 인간 폐암세포 A549를 사용하여 L. |
Al-Rimawi, F., Rishmawi, S., Arigat, S. H., Khalid, M. F., Warad, I. and Salah, Z. 2016. Anticancer activity, antioxidant activity, and phenolic and flavonoids content of wild Tragopogon porrifolius plant extracts. Evid. Based Complement. Alternat. Med. 2016, 9612490.
Bartek, J. and Lukas, J. 2001. Pathways governing G1/S transition and their response to DNA damage. FEBS Lett. 490, 117-122.
Bernardi, R., Liebermann, D. A. and Hoffman, B. 2000. Cdc25A stability is controlled by the ubiquitin-proteasome pathway during cell cycle progression and terminal differentiation. Oncogene 19, 2447-2454.
Bertero, T., Gastaldi, C., Bourget-Ponzio, I., Mari, B., Meneguzzi, G., Barbry, P., Ponzio, G. and Rezzonico, R. 2013. Cdc25A targeting by miR-483-3p decreases CCND-CDK4/6 assembly and contributes to cell cycle arrest. Cell Death Differ. 20, 800-811.
Biomberg, I. and Hoffmann, I. 1999. Ectopic expression of Cdc25A accelerates the G(1)/S transition and leads to premature activation of cyclin E- and cyclin A-dependent kinases. Mol. Cell Biol. 19, 6183-6194.
Cai, Z., Chehab, N. H. and Pavletich, N. P. 2009. Structure and activation mechanism of the CHK2 DNA damage checkpoint kinase. Mol. Cell 35, 818-829.
Choi, I. P. 2013. Reactive oxygen species and cancer. Hanyang Med. Rev. 33, 118-122.
Coulonval, K., Nockstaele, L., Paternot, S. and Roger, P. P. 2003. Phosphorylations of cyclin-dependent kinase 2 revisited using two-dimensional gel electrophoresis. J. Biol. Chem. 278, 52052-52060.
Devasagayam, T. P., Tilak, J. C., Boloor, K. K., Sane, K. S., Ghaskadbi, S. S. and Lele, R. D. 2004. Free radicals and antioxidants in human health: current status and future prospects. J. Assoc. Physicians India 52, 794-804.
Dickinson, B. C. and Chang, C. J. 2011. Chemistry and biology of reactive oxygen species in signaling or stress responses. Nat. Chem. Biol. 7, 504-511.
Donzelli, M. and Draetta, G. F. 2003. Regulating mammalian checkpoints through Cdc25 inactivation. EMBO Rep. 4, 671-677.
Dorai, T. and Aggarwal, B. B. 2004. Role of chemopreventive agents in cancer therapy. Cancer Lett. 215, 129-140.
Dulic, V., Kaufmann, W. K., Wilson, S. J., Tisty, T. D., Lees, E., Harper, J. W., Elledge, S. J. and Reed, S. I. 1994. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 76, 1013-1023.
Eymin, B., Claverie, P., Salon, C., Leduc, C., Col, E., Brambilla, E., Khochbin, S. and Gazzeri, S. 2006. p14ARF activates a Tip60-dependent and p53-independent ATM/ATR/CHK pathway in response to genotoxic stress. Mol. Cell Biol. 26, 4339-4350.
Falck, J., Mailand, N., Syljuasen, R. G., Bartek, J. and Lukas, J. 2001. The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis. Nature 410, 842-847.
Galaktionov, K., Lee, A. K., Eckstein, J., Draetta, G., Meckler, J., Loda, M. and Beach, D. 1995. CDC25 phosphatases as potential human oncogenes. Science 269, 1575-1577.
Gasparotto, D., Maestro, R., Piccinin, S., Vukosavljevic, T., Barzan, L., Sulfaro, S. and Boiocchi, M. 1997. Overexpression of CDC25A and CDC25B in head and neck cancers. Cancer Res. 57, 2366-2368.
GBD 2015 Risk Factors Collaborators. 2016. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 388, 1659-1724.
Gonzalez-Burgos, E. and Gomez-Serranillos, M. P. 2012. Terpene compounds in nature: a review of their potential antioxidant activity. Curr. Med. Chem. 19, 5319-5341.
Halliwell, B. H. and Gutteridge, J. M. C. 1990. Role of free radicals and catalytic metal ions in human disease: an overview. Methods Enzymol. 186, 1-85.
Hanahan, D. and Weinberg, R. A. 2000. The hallmarks of cancer. Cell 100, 57-65.
Hartwell, L. H. and Kastan, M. B. 1994. Cell cycle control and cancer. Science 266, 1821-1828.
Hoeijmakers, J. H. 2001. Genome maintenance mechanisms for preventing cancer. Nature 411, 366-374.
Ito, Y., Yoshida, H., Uruno, T., Takamura, Y., Miya, A., Kuma, K. K. and Miyauchi, A. 2004. Expression of cdc25A and cdc25B phosphatase in breast carcinoma. Breast Cancer 11, 295-300.
Jin, P., Gu, Y. and Morgan, D. O. 1996. Role of inhibitory CDC2 phosphorylation in radiation-induced G2 arrest in human cells. J. Cell Biol. 134, 963-970.
Kedare, S. B. and Singh, R. P. 2011. Genesis and development of DPPH method of antioxidant assay. J. Food Sci. Technol. 48, 412-422.
Mailand, N., Falck, J., Lukas, C., Syljuasen, R. G., Welcker, M., Bartek, J. and Lukas, J. 2000. Rapid destruction of Cdc 25A in response to DNA damage. Science 288, 1425-1429.
Malumbres, M. and Barbacid, M. 2009. Cell cycle, CDKs and cancer: a changing paradigm. Nat. Rev. Cancer 9, 153-166.
Mraz, M., Malinova, K., Kotaskova, J., Pavlova, S., Tichy, B., Malcikova, J., Stano, K. K., Smardova, J., Brychtova, Y., Doubek, M., Trbusek, M., Mayer, J. and Pospisilova, S. 2009. miR-34a, miR-29c and miR-17-5p are downregulated in CLL patients with TP53 abnormalities. Leukemia 23, 1159-1163.
Neergheen, V. S., Bahorun, T., Taylor, E. W., Jen, L. S. and Aruoma, O. I. 2010. Targeting specific cell signaling transduction pathways by dietary and medicinal phytochemicals in cancer chemoprevention. Toxicology 278, 229-241.
Niedzwiecki, A., Roomi, M. W., Kalinovsky, T. and Rath, M. 2016. Anticancer efficacy of polyphenols and their combinations. Nutrients 8, E552.
Nilsson, I. and Hoffmann, I. 2000. Cell cycle regulation by the Cdc25 phosphatase family. Prog. Cell Cycle Res. 4, 107-114.
O'Connor, P. M. 1997. Mammalian G1 and G2 phase checkpoints. Cancer Surv. 29, 151-182.
Rix, M. 2013. LITSEA POPULIFOLIA. Curtis's Botanical Magazine 30, 193-200.
Ryan, K. M., Phillips, A. C. and Vousden, K. H. 2001. Regulation and function of the p53 tumor suppressor protein. Curr. Opin. Cell Biol. 13, 332-337.
Singleton, V. L. and Rossi, J. A. 1965. Colorimetry of total phenolics with phosphomolybdic -phosphotungstic acid reagents. Am. J. Enol.Vitic. 16, 144-158.
Vermeulen, K., Van Bockstaele, D. R. and Berneman, Z. N. 2003. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif. 36, 131-149.
Vogelstein, B., Lane, D. and Levine, A. J. 2000. Surfing the p53 network. Nature 408, 307-310.
Wu, W., Fan, Y. H., Kemp, B. L., Walsh, G. and Mao, L. 1998. Overexpression of cdc25A and cdc25B is frequent in primary non-small cell lung cancer but is not associated with overexpression of c-myc. Cancer Res. 58, 4082-4085.
Xu, X., Yamamoto, H., Liu, G., Ito, Y., Ngan, C. Y., Kondo, M., Nagano, H., Dono, K., Sekimoto, M. and Monden, M. 2008. CDC25A inhibition suppresses the growth and invasion of human hepatocellular carcinoma cells. Int. J. Mol. Med. 21, 145-152.
Xu, X., Yamamoto, H., Sakon, M., Yasui, M., Ngan, C. Y., Fukunaga, H., Morita, T., Ogawa, M., Nagano, H., Nakamori, S., Sekimoto, M., Matsuura, N. and Monden, M. 2003. Overexpression of CDC25A phosphatase is associated with hypergrowth activity and poor prognosis of human hepatocellular carcinomas. Clin. Cancer Res. 9, 1764-1772.
Zhou, B. B. and Elledge, S. J. 2000. The DNA damage response: putting checkpoints in perspective. Nature 408, 433-439.
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
오픈액세스 학술지에 출판된 논문
※ AI-Helper는 부적절한 답변을 할 수 있습니다.